Cara Therapeutics reports Q4 net loss $0.59/share; prioritizes NP program, cash runway extended to 2026

Tvardi Therapeutics, Inc.

Net loss Q4 $32.3M ($0.59 per share) vs $30.3M ($0.56) prior year; full year loss $118.5M ($2.19) vs $85.5M ($1.59).
Total revenue Q4 $3.0M (down from $3.3M); FY 2023 $21.0M (down from $41.9M) on lower KORSUVA injection sales.
Completed enrollment of KOURAGE 1 Part A (214 patients); topline efficacy/safety data expected Q3 2024.
KORSUVA injection Q4 net sales $5.0M; TDAPA expires March 31, 2024; future reimbursement under ESRD PPS bundle.
Cash $100.8M at Dec 31, 2023; cash runway extended to 2026 via clinical prioritization, RIF, and HCR royalty deal ($36.5M net).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tvardi Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $3.0 million, net income $32.3 million, EPS $(0.59) per basic and diluted share.

Period: the fourth quarter ended December 31, 2023
Revenue: $3.0 million
Net income: $32.3 million
EPS: $(0.59) per basic and diluted share
Result: reported results

Exact text from the filing

For the fourth quarter of 2023, net loss was $32.3 million, or $(0.59) per basic and diluted share, compared to net loss of $30.3 million, or $(0.56) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $3.0 million and $3.3 million for the three months ended December 31, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-030494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.